Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that its Annual Report and Accounts for the year ended 31 December
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
A period of continued significant progress
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
Avacta has expanded its footprint in the US. The listing could be next.
Memorial Sloan Kettering Cancer Center and Fred Hutch Cancer Center are now open for patient enrolment to pre|CISION™ lead programme, AVA6000
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Launch Diagnostics is a leading independent distributor in the UK in-vitro diagnostics (IVD) market